{
    "cancer_info": {
        "cancer_name": "Cancer of Unknown Primary"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Complete history and physical exam (including breast, GU, pelvic, rectal, skin, oral cavity)",
            "CBC",
            "Creatinine",
            "Electrolytes",
            "LFTs",
            "LDH",
            "Urinalysis",
            "Calcium",
            "Hemoccult test",
            "PSA (men ≥40 years)",
            "Beta-hCG/alpha-fetoprotein (suspected germ cell tumors)",
            "Contrast-enhanced CT of chest/abdomen/pelvis",
            "FDG-PET/CT (if contrast contraindicated)",
            "Mammogram (if intact breast tissue)",
            "Breast MRI/ultrasound (if indicated)",
            "Core needle biopsy",
            "Fine needle aspiration (FNA) with cell block",
            "Rapid on-site evaluation (ROSE)",
            "Immunohistochemistry (IHC) for subtyping",
            "Endoscopy (for supraclavicular/head/neck nodes)",
            "CT/MRI (for supraclavicular nodes)",
            "CA-125 (for peritoneal ascites)",
            "AFP (for liver involvement)",
            "Liver-directed imaging",
            "Bone scan",
            "CNS-specific imaging",
            "Perineal/genital exam (for inguinal nodes)",
            "Cystoscopy",
            "Anal endoscopy",
            "p16/HPV/EBV testing (for head/neck nodes)",
            "PET/CT or PET/MRI (if contraindication to contrast)",
            "Multiparametric MRI (MPMRI) or 3D THRIVE MRI (for cervical nodes)",
            "In Situ Hybridization (ISH) for translocations",
            "Next-generation sequencing (NGS) for actionable mutations",
            "Biomarker testing (MMR/MSI status, TMB)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Favorable Subgroups",
            "risk_group": "Favorable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Women with isolated axillary nodes",
                    "plan_name": "Breast cancer management",
                    "plan_details": "Axillary dissection ± radiation/systemic therapy (breast regimen)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Squamous cell carcinoma in cervical nodes",
                    "plan_name": "Head/neck cancer regimen",
                    "plan_details": "Radiation ± chemoradiation",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Young men with mediastinal disease",
                    "plan_name": "Germ cell tumor regimen",
                    "plan_details": "Platinum-based chemotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Women with peritoneal ascites",
                    "plan_name": "Ovarian cancer regimen",
                    "plan_details": "Platinum-taxane chemotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "SCC in inguinal nodes",
                    "plan_name": "Lymph node dissection",
                    "plan_details": "Lymph node dissection ± radiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Colon-cancer profile (CK20+/CDX2+, CK7−)",
                    "plan_name": "FOLFOX/CAPOX",
                    "plan_details": "Oxaliplatin-based chemotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Poorly differentiated neuroendocrine carcinoma",
                    "plan_name": "Platinum/etoposide",
                    "plan_details": "Cisplatin/carboplatin + etoposide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Unfavorable Subgroups",
            "risk_group": "Unfavorable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Adenocarcinoma with disseminated disease",
                    "plan_name": "Carboplatin/paclitaxel",
                    "plan_details": "Carboplatin AUC 5-6 + paclitaxel 175-200mg/m²",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Adenocarcinoma with disseminated disease",
                    "plan_name": "Cisplatin/gemcitabine",
                    "plan_details": "Cisplatin 75mg/m² + gemcitabine 1250mg/m²",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Squamous cell carcinoma with disseminated disease",
                    "plan_name": "Carboplatin/paclitaxel",
                    "plan_details": "Carboplatin AUC 5-6 + paclitaxel 175-200mg/m²",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Squamous cell carcinoma with disseminated disease",
                    "plan_name": "mFOLFOX6",
                    "plan_details": "Oxaliplatin 85mg/m² + leucovorin 400mg/m² + fluorouracil bolus 400mg/m² + infusion 2400mg/m²",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Refractory adenocarcinoma",
                    "plan_name": "FOLFIRI",
                    "plan_details": "Irinotecan 180mg/m² + leucovorin 400mg/m² + fluorouracil bolus 400mg/m² + infusion 2400mg/m²",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other option"
                }
            ]
        },
        {
            "staging_criteria": "Biomarker-Driven",
            "risk_group": "Applicable to all subgroups",
            "treatment_plans": [
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "dMMR/MSI-H tumors",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "200mg IV every 3 weeks",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "TMB-H (≥10 mut/Mb) tumors",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "200mg IV every 3 weeks",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "NTRK fusion-positive tumors",
                    "plan_name": "TRK inhibitors",
                    "plan_details": "Entrectinib/larotrectinib/repotrectinib",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "BRAF V600E-mutant tumors",
                    "plan_name": "Dabrafenib + trametinib",
                    "plan_details": "Dabrafenib 150mg BID + trametinib 2mg daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "HER2 IHC 3+ tumors",
                    "plan_name": "Fam-trastuzumab deruxtecan",
                    "plan_details": "5.4mg/kg IV every 3 weeks",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "As indicated by biomarker",
                    "patient_subgroup": "RET fusion-positive tumors",
                    "plan_name": "Selpercatinib",
                    "plan_details": "160mg BID",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "dMMR/MSI-H: Defective DNA repair; rare in CUP (1.8%); predicts response to immune checkpoint inhibitors",
            "TMB-H (≥10 mut/Mb): High tumor mutational burden; predicts response to immune checkpoint inhibitors",
            "HER2 IHC 3+: Overexpression in solid tumors; indicates HER2-targeted antibody-drug conjugates",
            "RET fusion: Gene rearrangement; indicates RET inhibitor therapy",
            "BRAF V600E: Oncogenic driver mutation; indicates BRAF/MEK inhibitor therapy",
            "NTRK fusion: Rare gene fusion; indicates TRK inhibitor therapy",
            "PSA elevation: Suggests prostate primary; indicates androgen deprivation therapy",
            "HPV/p16+ (ISH): Indicates oropharyngeal primary in cervical SCC; guides site-specific therapy"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：不明原发部位肿瘤[CUP].txt"
}